{"id":8259,"date":"2026-07-20T15:10:42","date_gmt":"2026-07-20T12:10:42","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=8259"},"modified":"2026-07-20T15:30:25","modified_gmt":"2026-07-20T12:30:25","slug":"z-rostudirsen-fda-bla-accepted","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/z-rostudirsen-fda-bla-accepted\/","title":{"rendered":"Dyne Therapeutics, Duchenne Musk\u00fcler Distrofisi (DMD) i\u00e7in Ekzon 51 Atlama Tedavisi olan Z-Rostudirsen'e \u0130li\u015fkin ABD FDA Biyolojik \u00dcr\u00fcn Lisans Ba\u015fvurusunun (BLA) Kabul Edildi\u011fini Duyurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisinden (DMD) etkilenen aileler, Dyne Therapeutics&#039;nin ABD G\u0131da ve \u0130la\u00e7 \u0130daresi&#039;nin (FDA) z-rostudirsen (eski ad\u0131yla DYNE-251) i\u00e7in Biyolojik \u00dcr\u00fcn Lisans Ba\u015fvurusunu (BLA) kabul etti\u011fini duyurmas\u0131yla cesaret verici bir haber ald\u0131.<\/strong> Deney a\u015famas\u0131ndaki bu tedavi, ekzon 51 atlamas\u0131na uygun Duchenne kas distrofisi olan \u00e7ocuklar i\u00e7in geli\u015ftirilmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FDA numaral\u0131 patent ba\u015fvurusuna da \u00d6ncelikli \u0130nceleme stat\u00fcs\u00fc verilerek inceleme s\u00fcreci k\u0131salt\u0131ld\u0131 ve Re\u00e7eteli \u0130la\u00e7 Kullan\u0131c\u0131 \u00dccreti Yasas\u0131 (PDUFA) kapsam\u0131nda hedef i\u015flem tarihi 21 Ocak 2027 olarak belirlendi. Onaylanmas\u0131 halinde Dyne, z-rostudirsen&#039;i 2027 y\u0131l\u0131n\u0131n ilk \u00e7eyre\u011finde Amerika Birle\u015fik Devletleri&#039;nde piyasaya s\u00fcrmeyi planl\u0131yor.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#what-is-z-rostudirsen\">Z-Rostudirsen Nedir?<\/a><\/li><li><a href=\"#fda-accepts-biologics-license-application\">FDA Biyolojik \u00dcr\u00fcn Lisans Ba\u015fvurusunu Kabul Ediyor<\/a><\/li><li><a href=\"#why-is-accelerated-approval-important\">H\u0131zland\u0131r\u0131lm\u0131\u015f Onay Neden \u00d6nemli?<\/a><\/li><li><a href=\"#deliver-trial-results\">DELIVER Deneme Sonu\u00e7lar\u0131<\/a><\/li><li><a href=\"#dyne-therapeutics-plans-u-s-launch-in-early-2027\">Dyne Therapeutics'nin ABD'de 2027 y\u0131l\u0131n\u0131n ba\u015flar\u0131nda piyasaya s\u00fcr\u00fclmesi planlan\u0131yor<\/a><\/li><li><a href=\"#dynes-broader-duchenne-pipeline\">Dyne&#039;\u0131n Geni\u015fletilmi\u015f Duchenne Hastal\u0131klar\u0131 \u00dcr\u00fcn Yelpazesi<\/a><\/li><li><a href=\"#what-this-means-for-the-duchenne-community\">Bu, Duchenne Toplulu\u011fu \u0130\u00e7in Ne Anlama Geliyor?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"what-is-z-rostudirsen\" class=\"wp-block-heading\">Z-Rostudirsen Nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Z-rostudirsen (eskiden DYNE-251 olarak biliniyordu), ekzon 51 atlamas\u0131na uygun mutasyonlardan kaynaklanan Duchenne kas distrofisi olan bireyler i\u00e7in tasarlanm\u0131\u015f, deneysel bir ekzon atlama tedavisidir.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu terapi, terap\u00f6tik molek\u00fcllerin do\u011frudan iskelet ve kalp kas\u0131 h\u00fccrelerine iletilmesini iyile\u015ftirmek i\u00e7in tasarlanm\u0131\u015f, Dyne Therapeutics&#039;nin tescilli FORCE\u2122 platformunu kullanmaktad\u0131r. Kas dokusuna iletimi art\u0131rarak, tedavi, sa\u011fl\u0131kl\u0131 kas fonksiyonunun korunmas\u0131 i\u00e7in gerekli olan neredeyse tam uzunlukta distrofin proteininin \u00fcretimini art\u0131rmay\u0131 ama\u00e7lamaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kas dokusuna n\u00fcfuz etme olas\u0131l\u0131\u011f\u0131 s\u0131n\u0131rl\u0131 olabilen geleneksel ekzon bir g\u00fcvenlik profili korurken dokuya daha iyi n\u00fcfuz etmesini sa\u011flamak \u00fczere \u00f6zel olarak tasarlanm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha fazla bilgi edin<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/tr\/mutations-and-deletions-amenable-to-exon-51-skipping-therapies-dmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ekzon 51 Atlama Terapilerine Uygun Mutasyonlar ve Delesyonlar<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"fda-accepts-biologics-license-application\" class=\"wp-block-heading\">FDA Biyolojik \u00dcr\u00fcn Lisans Ba\u015fvurusunu Kabul Ediyor<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">FDA'n\u0131n Biyolojik \u00dcr\u00fcn Lisans Ba\u015fvurusunu (BLA) kabul etmesi, kurumun ba\u015fvurunun resmi bilimsel incelemeye ba\u015flanmas\u0131 i\u00e7in yeterince eksiksiz oldu\u011funa karar verdi\u011fi anlam\u0131na gelir. Daha Fazlas\u0131n\u0131 Okuyun: <a href=\"https:\/\/dmdwarrior.com\/tr\/biologics-license-application-bla\/\" target=\"_blank\" data-type=\"post\" data-id=\"5027\" rel=\"noreferrer noopener\">Biyolojik Lisans Ba\u015fvurusu (BLA)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu s\u00fcrecin bir par\u00e7as\u0131 olarak:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FDA numaral\u0131 ba\u015fvuruya \u00d6ncelikli \u0130nceleme stat\u00fcs\u00fc verilerek standart inceleme s\u00fcresi k\u0131salt\u0131lm\u0131\u015ft\u0131r.<\/strong><\/li>\n\n\n\n<li>PDUFA&#039;n\u0131n hedef uygulama tarihi 21 Ocak 2027 olarak belirlendi.<\/li>\n\n\n\n<li><strong>Ba\u015fvuru, dolayl\u0131 bir sonu\u00e7 \u00f6l\u00e7\u00fct\u00fc olarak distrofin \u00fcretimini esas alarak H\u0131zland\u0131r\u0131lm\u0131\u015f Onay talep etmektedir.<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">E\u011fer FDA \u00e7al\u0131\u015fmas\u0131, distrofin \u00fcretimindeki art\u0131\u015f\u0131n klinik fayday\u0131 makul bir \u015fekilde \u00f6ng\u00f6rebilece\u011fi sonucuna var\u0131rsa, z-rostudirsen, uzun vadeli klinik sonu\u00e7lar\u0131 do\u011frulamak i\u00e7in ek \u00e7al\u0131\u015fmalar devam ederken H\u0131zland\u0131r\u0131lm\u0131\u015f Onay alabilir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"why-is-accelerated-approval-important\" class=\"wp-block-heading\">H\u0131zland\u0131r\u0131lm\u0131\u015f Onay Neden \u00d6nemli?<\/h2>\n\n\n\n<h3 id=\"understanding-the-accelerated-approval-pathway\" class=\"wp-block-heading\">H\u0131zland\u0131r\u0131lm\u0131\u015f Onay S\u00fcrecini Anlamak<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi gibi nadir hastal\u0131klar i\u00e7in tedavi geli\u015ftirmek genellikle uzun y\u0131llar al\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hastalar\u0131n umut vadeden tedavilere daha erken eri\u015fimini sa\u011flamak amac\u0131yla, FDA, H\u0131zland\u0131r\u0131lm\u0131\u015f Onay yolunu olu\u015fturmu\u015ftur. Bu d\u00fczenleyici yol, klinik fayday\u0131 makul bir \u015fekilde tahmin etme olas\u0131l\u0131\u011f\u0131 y\u00fcksek olan bir ikincil sonlan\u0131m noktas\u0131na dayal\u0131 olarak onay verilmesine olanak tan\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi i\u00e7in distrofin \u00fcretimi, d\u00fczenleyici kurumlar taraf\u0131ndan de\u011ferlendirilen en \u00f6nemli dolayl\u0131 biyobelirte\u00e7lerden biri haline gelmi\u015ftir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">H\u0131zland\u0131r\u0131lm\u0131\u015f Onay alan \u015firketlerin, hastalar\u0131n uzun vadede anlaml\u0131 klinik faydalar elde etti\u011fini do\u011frulamak i\u00e7in pazarlama sonras\u0131 \u00e7al\u0131\u015fmalar\u0131na devam etmeleri genellikle zorunludur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Arac\u0131m\u0131z\u0131 \u015e\u0130MD\u0130 kullan\u0131n<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/tr\/duchenne-exon-deletion-tool\/\" target=\"_blank\" rel=\"noreferrer noopener\">DMD\/BMD Ekzon Analiz Arac\u0131<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"deliver-trial-results\" class=\"wp-block-heading\">DELIVER Deneme Sonu\u00e7lar\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">BLA ba\u015fvurusu, Faz 1\/2 DELIVER klinik \u00e7al\u0131\u015fmas\u0131n\u0131n kay\u0131t geni\u015fletme kohortundan elde edilen sonu\u00e7larla desteklenmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dyne Therapeutics \u00e7al\u0131\u015fmas\u0131na g\u00f6re, d\u00f6rt haftada bir z-rostudirsen alan kat\u0131l\u0131mc\u0131lar \u015fu sonu\u00e7lar\u0131 g\u00f6stermi\u015ftir:<\/p>\n\n\n\n<h3 id=\"significant-increase-in-dystrophin\" class=\"wp-block-heading\">Distrofinde \u00d6nemli Art\u0131\u015f<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Hastalar, distrofin \u00fcretiminde g\u00fc\u00e7l\u00fc ve istatistiksel olarak anlaml\u0131 bir art\u0131\u015f ya\u015fad\u0131lar; bu da ekzon atlama tedavisinin birincil biyolojik amac\u0131n\u0131 desteklemektedir.<\/p>\n\n\n\n<h3 id=\"improvements-across-multiple-functional-measures\" class=\"wp-block-heading\">Birden \u00c7ok Fonksiyonel \u00d6l\u00e7\u00fctte \u0130yile\u015fmeler<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Laboratuvar bulgular\u0131n\u0131n \u00f6tesinde, ara\u015ft\u0131rmac\u0131lar ayr\u0131ca \u00e7ok say\u0131da klinik fonksiyonel sonu\u00e7 noktas\u0131nda iyile\u015fmeler g\u00f6zlemlediler; bu da artan distrofinin daha iyi fiziksel performansa d\u00f6n\u00fc\u015febilece\u011fini d\u00fc\u015f\u00fcnd\u00fcrmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ek uzun vadeli \u00e7al\u0131\u015fmalar devam etmekte olsa da, bu fonksiyonel bulgular, tedaviyi destekleyen genel kan\u0131tlar\u0131 g\u00fc\u00e7lendirmektedir.<\/p>\n\n\n\n<h3 id=\"favorable-safety-profile\" class=\"wp-block-heading\">Olumlu G\u00fcvenlik Profili<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eirket ayr\u0131ca, \u00e7al\u0131\u015fma s\u00fcresi boyunca tedavinin genel olarak iyi tolere edildi\u011fini ve olumlu bir g\u00fcvenlik profili sundu\u011funu bildirdi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FDA inceleme s\u00fcrecinde g\u00fcvenlik, en \u00f6nemli hususlardan biri olmaya devam etmektedir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"dyne-therapeutics-plans-u-s-launch-in-early-2027\" class=\"wp-block-heading\">Dyne Therapeutics'nin ABD'de 2027 y\u0131l\u0131n\u0131n ba\u015flar\u0131nda piyasaya s\u00fcr\u00fclmesi planlan\u0131yor<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA onay\u0131n\u0131n planland\u0131\u011f\u0131 gibi verilmesi durumunda, Dyne Therapeutics, z-rostudirsen&#039;i 2027 y\u0131l\u0131n\u0131n ilk \u00e7eyre\u011finde Amerika Birle\u015fik Devletleri&#039;nde ticari olarak piyasaya s\u00fcrmeyi bekliyor.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eirket Ba\u015fkan\u0131 ve CEO&#039;su John Cox, amac\u0131n \u015fu sonu\u00e7lar\u0131 verebilecek bir terapi sunmak oldu\u011funu belirtti:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Neredeyse tam uzunlukta distrofinin g\u00fc\u00e7l\u00fc \u00fcretimi<\/li>\n\n\n\n<li>\u0130lgili kas dokular\u0131na geni\u015f \u00e7apl\u0131 iletim<\/li>\n\n\n\n<li>Duchenne kas distrofisi olan ki\u015filerde fonksiyonel iyile\u015fme<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eirket ayr\u0131ca, klinik geli\u015ftirme s\u00fcreci boyunca hastalar\u0131n, ailelerin, ara\u015ft\u0131rmac\u0131lar\u0131n, savunuculuk \u00f6rg\u00fctlerinin ve daha geni\u015f Duchenne toplulu\u011funun oynad\u0131\u011f\u0131 \u00f6nemli rol\u00fc de takdir etti.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"dynes-broader-duchenne-pipeline\" class=\"wp-block-heading\">Dyne&#039;\u0131n Geni\u015fletilmi\u015f Duchenne Hastal\u0131klar\u0131 \u00dcr\u00fcn Yelpazesi<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Z-rostudirsen, Dyne Therapeutics'in daha geni\u015f kapsaml\u0131 Duchenne kas distrofisi geli\u015ftirme program\u0131n\u0131n yaln\u0131zca bir par\u00e7as\u0131n\u0131 temsil etmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eirket ayr\u0131ca di\u011fer genetik mutasyonlar\u0131 hedefleyen, deneysel a\u015famada olan \u00e7e\u015fitli ekzon atlama terapilerini de geli\u015ftiriyor.<\/p>\n\n\n\n<h3 id=\"dyne-253\" class=\"wp-block-heading\">DYNE-253<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ekzon 53 atlamas\u0131na uygun hastalar i\u00e7in tasarlanm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<h3 id=\"dyne-245\" class=\"wp-block-heading\">DYNE-245<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ekzon 45 atlamas\u0131na uygun hastalar i\u00e7in tasarlanm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<h3 id=\"dyne-244\" class=\"wp-block-heading\">DYNE-244<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ekzon 44 atlamas\u0131na uygun hastalar i\u00e7in tasarlanm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<h3 id=\"dyne-255\" class=\"wp-block-heading\">DYNE-255<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ekzon 55 atlamas\u0131na uygun hastalar i\u00e7in tasarlanm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ba\u015far\u0131l\u0131 olmalar\u0131 durumunda, bu programlar Duchenne kas distrofisiyle ya\u015fayan bireylerin \u00e7ok daha b\u00fcy\u00fck bir b\u00f6l\u00fcm\u00fc i\u00e7in tedavi se\u00e7eneklerini geni\u015fletebilir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"what-this-means-for-the-duchenne-community\" class=\"wp-block-heading\">Bu, Duchenne Toplulu\u011fu \u0130\u00e7in Ne Anlama Geliyor?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">FDA'n\u0131n BLA'y\u0131 kabul etmesi, nihai bir onaydan ziyade \u00f6nemli bir d\u00fczenleyici d\u00f6n\u00fcm noktas\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak bu, \u015funu g\u00f6stermektedir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FDA, z-rostudirsen&#039;in resmi incelemesine ba\u015flad\u0131.<\/strong><\/li>\n\n\n\n<li>\u00d6ncelikli De\u011ferlendirme, tedavinin potansiyel \u00f6nemini yans\u0131t\u0131r.<\/li>\n\n\n\n<li>Bu uygulama, istatistiksel olarak anlaml\u0131 distrofin \u00fcretim verileri ve cesaret verici fonksiyonel sonu\u00e7larla desteklenmektedir.<\/li>\n\n\n\n<li><strong>D\u00fczenleyici bir karar\u0131n 21 Ocak 2027&#039;de verilmesi bekleniyor.<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Onaylanmas\u0131 halinde, z-rostudirsen, ekzon 51 atlamas\u0131na uygun Duchenne kas distrofisi olan bireyler i\u00e7in ba\u015fka bir tedavi se\u00e7ene\u011fi haline gelebilir ve bu y\u0131k\u0131c\u0131 genetik hastal\u0131\u011f\u0131n tedavi olanaklar\u0131n\u0131 daha da geni\u015fletebilir.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu Sayfay\u0131 Takip Edin<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/clinical-trials\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne i\u00e7in T\u00fcm Klinik Ara\u015ft\u0131rmalar<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Families affected by Duchenne muscular dystrophy (DMD) received encouraging news as Dyne Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for z-rostudirsen (formerly DYNE-251). The investigational therapy is being developed for people with Duchenne muscular dystrophy amenable to exon 51 skipping. The FDA has also granted [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8260,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[143,208,145,122,193,421,194,460],"class_list":["post-8259","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-dyne","tag-dyne-therapeutics","tag-dyne-251","tag-exon-51","tag-exon-51-skipping","tag-exon-51-skipping-therapy","tag-exon-51-treatment","tag-z-rostudirsen"],"subtitle":"FDA, z-rostudirsen i\u00e7in Dyne Therapeutics'nin Biyolojik Ruhsat Ba\u015fvurusunu kabul ederek, ekzon 51 atlamas\u0131na uygun Duchenne kas distrofisi tedavisi i\u00e7in \u00f6ncelikli \u0130nceleme stat\u00fcs\u00fc verdi. Bu d\u00f6n\u00fcm noktas\u0131n\u0131n ne anlama geldi\u011fini, Ocak 2027 PDUFA tarihini ve hastalar ve aileler i\u00e7in bundan sonra ne olaca\u011f\u0131n\u0131 \u00f6\u011frenin.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=8259"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8259\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/8260"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=8259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=8259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=8259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}